vTv Therapeutics receives termination notice for ppar-δ license from OnKure; effective Jan 2025

vTv Therapeutics Inc.

OnKure (formerly Reneo) notified vTv LLC intent to terminate the December 2017 License Agreement for vTv's ppar-δ agonist program IP.
OnKure has decided to discontinue development of the licensed program.
Termination becomes effective January 20, 2025.
Agreement had been previously amended in December 2021.
Financial impact of the termination was not disclosed by vTv.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.